Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease

Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.

The FDA has signed off on Sanofi’s oral drug venglustat to treat patients with type 3 Gaucher disease over a certain weight.

The once-daily pill, to be sold under the brand name Infilbray, is the first medicine approved by the agency that targets the neurological symptoms of the disease, according to the FDA’s announcement of the approval Wednesday evening.

Sign up for Blog Updates